Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Park, J., Hong, K., Kirpotin, D., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U., Marks, J., Moore, D., Papahadjopoulos, D., & Benz, C. Clinical Cancer Research, 8:1172-1181, 2002.
  author = {Park, J.W. and Hong, K. and Kirpotin, D.B. and Colbern, G. and Shalaby, R. and Baselga, J. and Shao, Y. and Nielsen, U.B. and Marks, J.D. and Moore, D. and Papahadjopoulos, D. and Benz, C.C.},
 journal = {Clinical Cancer Research},
 pages = {1172-1181},
 title = {Anti-{HER}2 immunoliposomes: {E}nhanced efficacy attributable to targeted delivery},
 volume = {8},
 year = {2002},
 title_with_no_special_chars = {AntiHER2 immunoliposomes Enhanced efficacy attributable to targeted delivery}

Downloads: 0